📊 ACBM Key Takeaways
Is Acro Biomedical Co., Ltd.. (ACBM) a Good Investment?
ACBM is in critical financial distress with zero revenue, negative stockholders' equity of -$387K, and unsustainable cash burn of -$196.3K in operating cash flow. The company's negative working capital (0.04x current ratio) and negative ROA of -717.4% indicate severe operational and financial deterioration with minimal viable asset base of only $14.1K against $326.9K in liabilities.
ACRO BIOMEDICAL's fundamentals are extremely weak: it generated no revenue, posted continuing operating and net losses, and consumed cash from operations with no evidence of a viable operating base. The balance sheet is severely distressed, with negative equity, very weak liquidity, and liabilities that far exceed assets, which raises substantial going-concern and financing risk.
Why Buy Acro Biomedical Co., Ltd.. Stock? ACBM Key Strengths
- Minimal long-term debt obligations
- Company still maintains some cash position ($4.1K)
- Public company status allows for potential restructuring options
- No long-term debt was reported, limiting exposure to long-duration borrowing costs
- Absolute annual cash burn is relatively small in dollar terms, which may modestly reduce near-term funding needs
- The cost structure appears simple, with no capital expenditure burden disclosed
ACBM Stock Risks: Acro Biomedical Co., Ltd.. Investment Risks
- Zero revenue generation with no apparent business operations
- Negative stockholders' equity indicating technical insolvency
- Liabilities exceed assets by $312.8K creating default risk
- Negative operating cash flow of -$196.3K unsustainable long-term
- Current ratio of 0.04x indicates inability to meet short-term obligations
- No insider buying activity suggesting lack of management confidence
- Zero revenue indicates no demonstrated operating business or earnings base
- Negative stockholders equity and a 0.04x current ratio signal severe balance-sheet and liquidity stress
- Persistent negative operating cash flow suggests continued dependence on external funding
Key Metrics to Watch
- Revenue generation and return to operations
- Cash burn rate and runway to insolvency
- Stockholders' equity recovery toward positive territory
- Current ratio improvement and working capital restructuring
- Operational cash flow stabilization
- Any return of recurring revenue and gross profit generation
- Cash balance versus quarterly operating cash burn and changes in stockholders equity
Acro Biomedical Co., Ltd.. (ACBM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ACBM Profit Margin, ROE & Profitability Analysis
ACBM vs Services Sector: How Acro Biomedical Co., Ltd.. Compares
How Acro Biomedical Co., Ltd.. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Acro Biomedical Co., Ltd.. Stock Overvalued? ACBM Valuation Analysis 2026
Based on fundamental analysis, Acro Biomedical Co., Ltd.. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Acro Biomedical Co., Ltd.. Balance Sheet: ACBM Debt, Cash & Liquidity
ACBM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Acro Biomedical Co., Ltd..'s revenue has declined by 85% over the 5-year period, indicating business contraction. The most recent EPS of $0.00 indicates the company is currently unprofitable.
ACBM Revenue Growth, EPS Growth & YoY Performance
ACBM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$10.1K | $0.00 |
| Q2 2025 | N/A | -$10.1K | $0.00 |
| Q1 2025 | N/A | -$10.3K | $0.00 |
| Q3 2024 | N/A | -$10.1K | $0.00 |
| Q2 2024 | N/A | -$10.1K | $0.00 |
| Q1 2024 | N/A | -$11.3K | $0.00 |
| Q3 2023 | N/A | -$1.6M | $-0.03 |
| Q2 2023 | N/A | -$3.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Acro Biomedical Co., Ltd.. Dividends, Buybacks & Capital Allocation
ACBM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Acro Biomedical Co., Ltd.. (CIK: 0001622996)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACBM
What is the AI rating for ACBM?
Acro Biomedical Co., Ltd.. (ACBM) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACBM's key strengths?
Claude: Minimal long-term debt obligations. Company still maintains some cash position ($4.1K). ChatGPT: No long-term debt was reported, limiting exposure to long-duration borrowing costs. Absolute annual cash burn is relatively small in dollar terms, which may modestly reduce near-term funding needs.
What are the risks of investing in ACBM?
Claude: Zero revenue generation with no apparent business operations. Negative stockholders' equity indicating technical insolvency. ChatGPT: Zero revenue indicates no demonstrated operating business or earnings base. Negative stockholders equity and a 0.04x current ratio signal severe balance-sheet and liquidity stress.
What is ACBM's revenue and growth?
Acro Biomedical Co., Ltd.. reported revenue of $0.0.
Does ACBM pay dividends?
Acro Biomedical Co., Ltd.. does not currently pay dividends.
Where can I find ACBM SEC filings?
Official SEC filings for Acro Biomedical Co., Ltd.. (CIK: 0001622996) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACBM's EPS?
Acro Biomedical Co., Ltd.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACBM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Acro Biomedical Co., Ltd.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACBM stock overvalued or undervalued?
Valuation metrics for ACBM: ROE of N/A (sector avg: 16%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy ACBM stock in 2026?
Our dual AI analysis gives Acro Biomedical Co., Ltd.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACBM's free cash flow?
Acro Biomedical Co., Ltd..'s operating cash flow is $-196.3K, with capital expenditures of N/A.
How does ACBM compare to other Services stocks?
Vs Services sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 16%), current ratio 0.04 (avg: 1.5).